Bionano Genomics Valuation Multiples

Bionano Genomics is valued at $17M as of October 2026, a 0.4x revenue multiple. In the last 12 months, Bionano Genomics revenue was $32M.

Bionano Genomics Overview

About Bionano Genomics

Bionano Genomics is a San Diego life-sciences tools company founded in 2007 and listed on Nasdaq under BNGO. It develops optical genome mapping instruments, consumables and software used to detect structural genomic variation. Research laboratories, hospitals and pharmaceutical customers use its Saphyr platform and related informatics in cytogenetics and translational research. Revenue comes from instrument and consumable sales, software and laboratory services. Bionano expanded into genetic testing through the 2020 acquisition of Lineagen. It added BioDiscovery's NxClinical informatics platform in 2021 and Purigen's Ionic Purification System in 2022. These acquisitions broadened the company from a single instrument platform into an end-to-end genome analysis workflow. It remains the public operating company at bionano.com.


Founded

2007

HQ

United States

Employees

100

Financials (LTM)

Revenue: $32M
Net Income: ($29M)

EV

$14M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bionano Genomics Financials

Bionano Genomics reported last 12-month revenue of $32M.

In the same LTM period, Bionano Genomics generated $16M in gross profit and had net loss of ($29M).

Revenue (LTM)


Bionano Genomics P&L

In the most recent fiscal year, Bionano Genomics reported revenue of $29M and EBITDA of ($21M).

Bionano Genomics is unprofitable as of last fiscal year, with gross margin of 46%, EBITDA margin of (74%), and net margin of (93%).

See analyst estimates for Bionano Genomics
LTMLast FY202320242025202620272028
Revenue$32M$29M$36M$31M$29M
Gross Profit$16M$13M$10M$380K$13M
Gross Margin50%46%26%1%46%
EBITDA-($21M)($225M)($97M)($21M)
EBITDA Margin-(74%)(623%)(317%)(74%)
EBIT Margin(94%)(117%)(380%)(248%)(117%)
Net Profit($29M)($26M)($232M)($112M)($26M)
Net Margin(91%)(93%)(644%)(364%)(93%)
Net Debt-$4M---

Financial data powered by Morningstar, Inc.

Bionano Genomics Stock Performance

Bionano Genomics has current market cap of $17M, and enterprise value of $14M.

Market Cap Evolution


Bionano Genomics' stock price is $1.47.

Bionano Genomics share price decreased by 6.4% in the last 30 days, and by 17.9% in the last year.

Bionano Genomics has an EPS (earnings per share) of $-2.24.

See more trading valuation data for Bionano Genomics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$14M$17M0.7%-6.4%37.4%-17.9%$-2.24

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bionano Genomics Valuation Multiples

Bionano Genomics trades at 0.4x EV/Revenue multiple, and (0.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Bionano Genomics

EV / Revenue (LTM)


Bionano Genomics Financial Valuation Multiples

As of October 9, 2026, Bionano Genomics has market cap of $17M and EV of $14M.

Bionano Genomics has a P/E ratio of (0.6x).

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.5x0.4x0.5x0.5x
EV/EBITDA-(0.7x)(0.1x)(0.1x)(0.7x)
EV/EBIT(0.5x)(0.4x)(0.1x)(0.2x)(0.4x)
EV/Gross Profit0.9x1.1x1.5x37.1x1.1x
P/E(0.6x)(0.7x)(0.1x)(0.2x)(0.7x)
EV/FCF-(0.9x)(0.1x)(0.2x)(0.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bionano Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bionano Genomics Margins & Growth Rates

Bionano Genomics grew revenue by 14% and net profit by 11% in the last fiscal year.

In the most recent fiscal year, Bionano Genomics reported gross margin of 46%, EBITDA margin of (74%), and net margin of (93%).

See estimated margins and future growth rates for Bionano Genomics

Bionano Genomics Margins

Last FY202420252026202720282029
Gross Margin46%1%46%50%
EBITDA Margin(74%)(317%)(74%)-
EBIT Margin(117%)(248%)(117%)(88%)
Net Margin(93%)(364%)(93%)(90%)
FCF Margin(57%)(224%)(57%)-

Bionano Genomics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth14%(15%)(7%)14%
Gross Profit Growth22%(96%)3370%22%
EBITDA Growth-(57%)(78%)-
EBIT Growth(14%)(44%)(56%)(14%)
Net Profit Growth11%(52%)(76%)11%
FCF Growth-(46%)(76%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Bionano Genomics Operational KPIs

Bionano Genomics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Bionano Genomics
LTMLast FY202320242025202620272028
Revenue per Employee-$0.3M---
Opex per Employee-$0.5M---
R&D Expenses to Revenue38%40%150%81%40%
Opex to Revenue-163%622%339%163%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bionano Genomics Competitors

Bionano Genomics competitors include Biosynex, European Medical Solutions, Rhythm Biosciences, OncoSil Medical, Lifeward, Lifecare, SeaStar Medical Holding, Urteste, Elbit Realestate and Labo Euromedis.

Most Bionano Genomics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Biosynex$107M($2M)0.7x0.7x(40.5x)(4.9x)
European Medical Solutions$56M$5M0.6x-7.0x-
Rhythm Biosciences$59K($4M)261.1x-(3.9x)-
OncoSil Medical$1M($8M)11.6x8.4x(1.8x)(1.8x)
Lifeward$22M($19M)0.7x0.6x(0.8x)-
Lifecare$12K($12M)1273.2x184.3x(1.3x)(1.8x)
SeaStar Medical Holding$1M($12M)9.3x6.3x(0.9x)-
Urteste$6K($1M)2913.4x-(11.3x)-

This data is available for Pro users. Sign up to see all Bionano Genomics competitors and their valuation data.

Start Free Trial

Bionano Genomics VC Funding History

Before going public, Bionano Genomics raised $120M in total equity funding, across 5 rounds.


Bionano Genomics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Aug-16Series DNovartis Venture Fund; Domain Associates; LC Ventures$32M--
Mar-16Series DNovartis Venture Fund; Domain Associates; Legend Capital$10M--
Feb-15Series C-$15M-Bionano Genomics completed a $53 million Series C financing round in November 2014, with a follow-on Series C-II in January/February 2015. Investors included Novartis Venture Fund, Federated Kaufmann Fund, Monashee Investment Management, Legend Capital, Domain Associates, Battelle Ventures, and Gund Investment Corporation. Darren Cai from Legend Capital and Campbell Murray from Novartis Venture Fund joined the board. The funds supported commercialization of the Irys platform for genome mapping, detection of structural variations, development of next-generation platforms, and technology innovations. The Irys system addresses structural variations like insertions, deletions, inversions, translocations, and repeats, often missed by other genomics tools, positioning it for personalized medicine and diagnostics.
Nov-14Series CNovartis Venture Fund; Domain Associates; Battelle Ventures; Gund Investment, LLC; Legend Capital$53M-Bionano Genomics, originally founded in 2008 as BioNanomatrix, develops genome mapping technology to detect long-range genomic information for applications like cancer treatment. The company closed a $53 million Series C funding round on November 20, 2014, co-led by Legend Capital and Novartis Venture Fund, with participation from Battelle Ventures, Domain Associates, Gund Investment Corporation, Federated Kaufmann Fund, and Monashee Investment Management. This round brought total funding to approximately $113 million in debt and equity. Legend Capital executive director Darren Cai and Novartis Venture Fund managing director Campbell Murray joined the board. Proceeds from the Series C were allocated to accelerate commercialization of the Irys platform and initiate development of next-generation platforms. Past investors included KT Venture Group, the corporate venturing arm of KLA-Tencor.
Oct-13Series CDomain Associates; Battelle Ventures; Gund Investment, LLC$10M-BioNano Genomics raised $10 million in financing on October 2, 2013, from existing investors Battelle Ventures, Domain Associates, and Gund Investment Corporation to support development and commercialization of the Irys system for human genome analysis. The Irys system enables direct observation of native genomic structure through imaging of long molecules, detecting structural variation, improving genome assemblies, and phasing haplotypes, with scalability demonstrated for large genomes like human. The funding aimed to expand commercialization efforts in the U.S., China, and Europe for biomedical disease research and diagnostic development in genomics and epigenomics.

Acquisitions by Bionano Genomics

Bionano Genomics has acquired 3 companies to date.

Last acquisition by Bionano Genomics was on November 28th 2022. Bionano Genomics acquired Purigen Biosystems for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Bionano Genomics

Purigen Biosystems
BioDiscovery
Lineagen
Description
Purigen Biosystems was a California life-sciences tools company founded in 2012. It developed the Ionic Purification System, which uses isotachophoresis to isolate DNA and RNA from low-input and difficult biological samples. Academic, clinical and pharmaceutical laboratories used the instrument and consumables before sequencing and genomic analysis. Revenue came from instrument, consumable and service sales. Bionano Genomics announced the acquisition on 28 November 2022 and completed it on 30 November. Bionano paid USD 32 million in cash at closing and agreed to potential additional cash payments tied to development and commercial milestones. The purchase added sample preparation to Bionano's optical genome mapping workflow and retained Purigen personnel. Purigen is now an acquired Bionano operation rather than an independent biotechnology company.
BioDiscovery was a US scientific-software company founded in 1997 and based in the Los Angeles area. It developed NxClinical and related tools for copy-number, structural-variant and sequence analysis across next-generation sequencing and microarray data. Clinical cytogenetics laboratories, research institutions and pharmaceutical users licensed the software for genomic interpretation workflows. Revenue came from software subscriptions, licences and related support. Bionano Genomics announced an agreement to acquire BioDiscovery on 12 October 2021 and completed the purchase on 18 October. The combination brought BioDiscovery's informatics customer base and development team into Bionano's optical genome mapping platform. Founder Soheil Shams joined Bionano as chief informatics officer. BioDiscovery is now an acquired Bionano business and is distinct from similarly named funds and drug-discovery companies.
Lineagen was a Salt Lake City molecular-diagnostics company founded in 2002. It provided genetic testing and counselling for children and families affected by autism and other neurodevelopmental disorders. Clinicians used its laboratory-developed tests and chromosomal microarray services to identify potentially relevant genomic variants. The business generated testing and service revenue through a CLIA-certified laboratory and payer relationships. Bionano Genomics acquired Lineagen through a merger completed on 21 August 2020 and announced the transaction on 24 August. The transaction added a clinical laboratory, genetic counsellors, billing expertise and payer contracts to Bionano's optical genome mapping business. Lineagen is now an acquired Bionano operation rather than an independent diagnostics company.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Ann Arbor, MI
Salt Lake City, UT
Deal Date28 Nov 202212 Oct 202124 Aug 2020
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bionano Genomics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bionano Genomics

When was Bionano Genomics founded?Bionano Genomics was founded in 2007.
Where is Bionano Genomics headquartered?Bionano Genomics is headquartered in United States.
How many employees does Bionano Genomics have?As of today, Bionano Genomics has over 100 employees.
Who is the CEO of Bionano Genomics?Bionano Genomics' CEO is R. Erik Holmlin.
Is Bionano Genomics publicly listed?Yes, Bionano Genomics is a public company listed on Nasdaq.
What is the stock symbol of Bionano Genomics?Bionano Genomics trades under BNGO ticker.
When did Bionano Genomics go public?Bionano Genomics went public in 2018.
Who are competitors of Bionano Genomics?Bionano Genomics main competitors include Biosynex, European Medical Solutions, Rhythm Biosciences, OncoSil Medical, Lifeward, Lifecare, SeaStar Medical Holding, Urteste, Elbit Realestate, Labo Euromedis.
What is the current market cap of Bionano Genomics?Bionano Genomics' current market cap is $17M.
What is the current revenue of Bionano Genomics?Bionano Genomics' last 12 months revenue is $32M.
What is the current revenue growth of Bionano Genomics?Bionano Genomics revenue growth (NTM/LTM) is 29%.
What is the current EV/Revenue multiple of Bionano Genomics?Current revenue multiple of Bionano Genomics is 0.4x.
Is Bionano Genomics profitable?No, Bionano Genomics is not profitable.
What is the current net income of Bionano Genomics?Bionano Genomics' last 12 months net income is ($29M).
How many companies Bionano Genomics has acquired to date?As of October 2026, Bionano Genomics has acquired 3 companies.
What was the largest acquisition by Bionano Genomics?None of the M&A deals Bionano Genomics has completed have disclosed valuations.
What companies Bionano Genomics acquired?Bionano Genomics acquired BioDiscovery, Purigen Biosystems, and Lineagen.
In how many companies Bionano Genomics has invested to date?Bionano Genomics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Bionano Genomics

Lists including Bionano Genomics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial